Visão geral da empresa
A clinical-stage biopharmaceutical entity, Zentalis Pharmaceuticals, Inc. is dedicated to the discovery and development of small molecule therapeutics specifically designed for the treatment of various cancers within the United States. The company operates within the Healthcare sector, specifically in the Biotechnology industry, a classification that typically implies a focus on research-intensive activities with significant risk profiles associated with clinical trial outcomes. Currently, the organization employs 106 individuals and holds a market capitalization of $195.77M. The absence of reported annual revenue in the available data suggests that the company is still in a developmental phase where expenses for research and development likely outweigh generated sales, a common characteristic for early-stage biotechnology firms. This specific market cap and revenue profile indicate that Zentalis is a mid-to-small cap biotech firm whose valuation is primarily driven by the potential future success of its pipeline rather than current profitability or cash flow generation.
Saúde financeira
The financial statements for the trailing twelve months reflect a Net Income of $-137,060,000 and an EBITDA of $-140,136,992, while Revenue is reported as N/A. The substantial gap between the reported Net Income and EBITDA figures, both of which are deeply negative, reveals a cost structure dominated by operational expenses such as clinical trial costs and personnel, where non-operating items or tax impacts are negligible in the current context. The company reports Free Cash Flow of $-75,869,504, indicating a significant cash outflow that necessitates external financing or the drawdown of existing cash reserves to sustain operations. All three margin metrics—the Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved commercial sales sufficient to generate a positive margin on its revenue base. On the liability side, the company holds $245.89M in Cash against $39.58M in Debt, resulting in a Debt to Equity ratio of 18.30, which suggests a conservative balance sheet structure where cash assets far exceed debt obligations. Liquidity is further supported by a Current Ratio of 6.93, a high figure that indicates a robust ability to meet short-term obligations with current assets. Finally, the Return on Equity stands at -49.5% and the Return on Assets at -24.5%, metrics that reveal that management has not yet been able to generate positive returns on the capital invested, reflecting the early-stage nature of the business.
Avaliação de valorização
The valuation metrics show a Trailing P/E Ratio (TTM) as N/A and a Forward P/E of -1.63. The discrepancy between these two figures, where the forward P/E is negative, implies that the market expects the company to remain unprofitable in the immediate future, preventing a meaningful earnings-based valuation for the next reporting period. The Price to Book ratio is 0.88, indicating that the company's market capitalization trades at a discount to its net asset value, suggesting the market does not currently assign a significant premium to the intangible value of the clinical pipeline relative to the tangible assets. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of 0.07, are difficult to interpret in a traditional sense due to the lack of positive earnings and sales, but the low EV/EBITDA suggests the enterprise value is not priced at a multiple of negative earnings in the conventional sense. The stock's recent trading range spans a 52-Week High of $3.95 and a 52-Week Low of $1.01. Without a specific current price in the provided facts, the valuation position relative to this range remains undefined, though the wide spread between the high and low highlights significant volatility over the past year. The Beta of 1.66 indicates that the stock price is expected to be 66% more volatile than the broader market, reflecting the high risk profile associated with clinical-stage biotechnology investments.
Growth & Income
The available data lists Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, as the company has not yet generated the consistent revenue streams required to calculate year-over-year growth rates. Because the company is in a clinical-stage development phase rather than a commercial revenue generation phase, earnings are not growing faster or slower than revenue in a traditional sense, as both are currently non-existent or negligible. Regarding income distribution, the company has a Dividend Yield of N/A and a Payout Ratio of 0.0%, confirming that it does not distribute dividends to shareholders. Instead, the company reinvests all available earnings and cash reserves into research and development activities to advance its therapeutic candidates through clinical trials. Consequently, the overall growth and income profile of Zentalis Pharmaceuticals, Inc. is characterized by a complete lack of dividend income and a focus on capital appreciation potential derived solely from the successful progression of its drug candidates, rather than current profitability or cash distributions.